Product Description
MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy. MVR CAR-T can also be used in patients who relapse after CD19 CAR-T treatment. Reduction of cytokine secretion due to selective killing of tumor cells. (Sourced from: http://www.eutilex.com/en/sub3/sub1_view.php?idx=7)
Mechanisms of Action: CAR-T,MVR
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eutilex
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for EU-301](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|